Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01116843
Other study ID # WS590266
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received May 3, 2010
Last updated July 8, 2015
Start date May 2010
Est. completion date February 2014

Study information

Verified date July 2015
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review CommitteeCanada: Health Canada
Study type Interventional

Clinical Trial Summary

The objective of this study is to assess the biological effects in the primary tumor following a short, pre-operative course of treatment with PF-00298804 in patients with Oral Cavity Cancer.


Description:

This is a single-center, randomized, double-blinded, biomarker driven, preoperative window of opportunity study with a pharmacodynamic primary endpoint. Patients with resectable, histologically confirmed OCC for whom surgical treatment is planned as definitive management, will be randomized 2:1 to receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days or to Matching Placebo for 7-11 days depending on surgery schedule. The target is a total of 8 days of treatment but with a minimum of 7 and a maximum of 11 dosing days. All patients will receive surgery as per standard of care without delay. Biomarkers from the surgical specimen and baseline tumor biopsy or consent to provide a tumor block from existing primary diagnostic tumor biopsy completed within 90 days will be evaluated for primary and secondary pharmacodynamic endpoints.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date February 2014
Est. primary completion date February 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Signed, voluntary informed consent provided

- Willing and able to comply with scheduled visits, treatment plan, tests, other study procedures

- Patient must be diagnosed with histologically confirmed oral cavity squamous cell carcinoma (OCC) (lip, floor of mouth, anterior 2/3 tongue, buccal mucosa, upper and lower gingiva, hard palate and retromolar trigone) considered resectable (T1-4a, N0-2, M0; (without distant metastases)) for whom surgical resection of tumor is planned. Patients with distant metastatic disease or diagnosis of SCCHN may not be enrolled

- Must be able to provide a fresh tumor biopsy prior to randomization for histopathological and biomarker evaluation. No anti-neoplastic treatment allowed between obtaining baseline tumor specimen and randomization. Patients who decline an in-house fresh pre-treatment tumor biopsy must give consent to provide a tumor block from an existing diagnostic primary tumor biopsy completed within 90 days of enrolment

- Prior treatment with agents targeted to epidermal growth factor receptor is not allowed.

- No prior chemotherapy or radiotherapy (to primary site/nodes).

- Patient must not have received prior anti-neoplastic treatment within past 2 years

- Any treatment-related acute toxicity, including laboratory abnormalities, must have recovered to CTCAE Grade 1 (v.4.0) or baseline, except toxicity not considered a safety risk.

- ECOG performance status of 0-2.

- Patient must have adequate organ function as determined by the following criteria:

- Serum creatinine = 1.5 ULN or a calculated creatinine clearance of = 50 mL/min

- Absolute neutrophil count = 1.5 x 109/L

- Leukocytes > 3.0 x 109/L

- Hemoglobin > 80 g/L

- Platelets > 100 x 109/L

- Total bilirubin < ULN

- AST (SGOT) and ALT (SGPT) < 2.5 x ULN

- 12-Lead ECG with normal tracing, or clinically non-significant changes that do not require medical intervention

- QTc interval < 470 msec, and without history of Torsades de Pointes or other symptomatic QTc abnormality

- A normal LVEF of >50% as measured by ECHO or MUGA within 4 weeks prior to start of study treatment will be required for all patients

Exclusion Criteria:

- Patients who require segmental mandibulectomy for surgical resection of oral cavity tumor will not be enrolled

- Primary site of head and neck carcinoma in nasopharynx, skin, or unknown

- Prior or concurrent radiation therapy to tumor at site of planned resection

- Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of PF-00299804

- Requirement for treatment with drugs that are highly dependent on CYP2D6 for metabolism since PF-00299804 is a potent CYP2D6 inhibitor in in vitro assays

- Patients currently taking drugs that have a risk of causing Torsades de Pointes

- Any acute or chronic medical, psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or trial drug administration or could interfere with interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry in the trial

- Other serious uncontrolled medical disorder or active infection that would impair the ability to receive study treatment as determined by investigator

- Dementia or significantly altered mental status that would limit the ability to obtain informed consent and compliance with the requirements of this protocol

- Patients breastfeeding or pregnant are excluded. All female patients with reproductive potential must have a negative pregnancy test within 72 hours prior to treatment.

- Patients of reproductive potential or their partners must agree to use effective contraception while receiving trial treatment and for at least 3 months thereafter.

- Current enrollment in another therapeutic clinical trial

- Inability/lack of willingness to comply with visits, treatment plans, protocol assessments or laboratory tests

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
PF-00299804
PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.

Locations

Country Name City State
Canada Princess Margaret Hospital Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
University Health Network, Toronto Pfizer

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the degree of modulation of the proliferation index, ki-67, in the primary tumor of OCC specimens following a short, preoperative course of PF-00299804 8-11 months No
Secondary To evaluate changes in tissue and blood-based biomarkers before, during and after treatment with PF-00299804 and attempt to correlate with gene expression changes, EGFR variant III mutation status, EGFR amplification and histopathological changes 8-11 months No
Secondary To assess the relationship between pharmacokinetic parameters and molecular changes detected in OCC tumor specimens 8-11 months No
Secondary To assess the safety and tolerability of pre-operative PF-00299804 8-11 months Yes
Secondary To quantitatively assess the effect of PF-00299804 on tumorigenic cells expressing CD44+/Lin- markers in paired OCC tumor specimens 8-11 months No
Secondary To evaluate gene expression changes in tumor tissue before and after treatment with PF00299804 8-11 months No
See also
  Status Clinical Trial Phase
Completed NCT01695122 - Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Recruiting NCT01958762 - Screening for Cancers in the Oral CAvity N/A
Recruiting NCT05429099 - Mandibular Reconstruction Preplanning (ViPMR) Phase 2/Phase 3
Recruiting NCT05757817 - Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae N/A
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Recruiting NCT04809324 - Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers N/A
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Terminated NCT03555721 - CytID Analysis of Oral Lesions
Recruiting NCT05375266 - Immune Biomarker Study for Head and Neck Cancer
Active, not recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Completed NCT03096808 - Adaptive Radiotherapy for Head and Neck Cancer Phase 2
Completed NCT00359645 - Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Phase 3
Completed NCT02412241 - Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients N/A
Terminated NCT00934739 - A Study of High-Risk Oral Cavity Cancer Phase 2/Phase 3
Not yet recruiting NCT06407570 - Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment
Recruiting NCT05337631 - Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
Recruiting NCT05927220 - WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA
Recruiting NCT05369234 - Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis Phase 3
Completed NCT05056064 - Efficacy of Swallowing Function After Early Postoperative Oral Exercise Among Patient With Oral Cavity Cancer Underwent Flap Reconstruction N/A